Sources
The medical pages link sources near the claims they support. This page gathers those sources in one place.
GAD65 ataxia is rare. There are not many large studies. Much of what doctors know comes from reviews, small studies and case reports. That can still be useful evidence, but it leaves uncertainty for individual patients.
Patient-facing sources explain basic terms and practical care. Research papers explain what is known about GAD65 ataxia, but many are small, retrospective or built on earlier evidence.
Last reviewed: Aug. 22, 2026.
This patient-facing overview explains ataxia as a coordination problem and lists common symptoms, including walking, balance, speech and swallowing problems.
This NHS treatment page describes team-based care for ataxia, including physical therapy, occupational therapy and speech therapy. The daily-life and rehab pages use it for practical care needs rather than GAD65-specific treatment claims.
MedlinePlus gives general background on cerebellar disorders and why problems in the cerebellum can affect movement. It helps explain why the same symptom, ataxia, can have different causes and treatment paths.
MedlinePlus explains autoimmunity in plain language: the immune system mistakenly attacks healthy cells, tissues or organs. That background helps define autoantibodies before the site turns to rare neurologic disease.
The CDC page lists practical fall-prevention steps, including medication review, vision checks, balance and strength work when appropriate, and home safety changes. It informs the daily-life checklist without making those steps specific to every patient.
This is the U.S. crisis line reference used in the mental-health section. It gives readers a direct option when someone may be at immediate risk of self-harm.
These guidelines review immune-mediated cerebellar ataxias and the treatments reported for GAD antibody-linked cases. The treatment page uses them to name possible immune therapies while keeping expectations cautious.
This review lays out the main immune-related ataxia categories and the practical difficulty of treating rare disorders with limited trial evidence. It is used for the site's discussion of timing, evidence limits and variable outcomes.
This paper reviews evidence that some anti-GAD antibodies may affect cerebellar GABA signaling, while also discussing unresolved questions about whether the antibodies directly cause symptoms.
This GAD65 ataxia cohort followed patients after immune treatment. It supports the treatment page's cautious point that improvement can happen, especially when symptoms come on over weeks and treatment starts sooner.
This Mayo Clinic study describes the clinical spectrum seen with high GAD65 antibody levels, including ataxia and other neurologic syndromes. The diagnosis and overview pages use it to explain why the antibody result has to be interpreted with symptoms, exam findings and imaging.
Brown and colleagues examine how GAD antibody results are used in neurologic practice and why interpretation can be difficult. The review is a key source for the site's warning that a lab number alone cannot prove the diagnosis or predict treatment response.
This 2025 Johns Hopkins study compares people with GAD65-associated pure cerebellar ataxia and people with stiff-person spectrum symptoms. It adds recent evidence that GAD65-related ataxia can be disabling in more than one clinical pattern.
This JAMA Neurology study looks at treatment responses and outcomes in adults with autoimmune cerebellar ataxia. It gives the treatment page a broader context: improvement can happen, but results vary by the type of immune-related ataxia.
This review summarizes GAD65 neurologic autoimmunity across several syndromes, including cerebellar ataxia, stiff-person syndrome, epilepsy and limbic encephalitis. It also connects GAD65 antibodies with other autoimmune diseases, which is central to the site's overview page.